Your browser doesn't support javascript.
loading
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Andraos, Rita; Qian, Zhiyan; Bonenfant, Débora; Rubert, Joëlle; Vangrevelinghe, Eric; Scheufler, Clemens; Marque, Fanny; Régnier, Catherine H; De Pover, Alain; Ryckelynck, Hugues; Bhagwat, Neha; Koppikar, Priya; Goel, Aviva; Wyder, Lorenza; Tavares, Gisele; Baffert, Fabienne; Pissot-Soldermann, Carole; Manley, Paul W; Gaul, Christoph; Voshol, Hans; Levine, Ross L; Sellers, William R; Hofmann, Francesco; Radimerski, Thomas.
Afiliación
  • Andraos R; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Qian Z; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Bonenfant D; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Rubert J; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Vangrevelinghe E; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Scheufler C; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Marque F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Régnier CH; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • De Pover A; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Ryckelynck H; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Bhagwat N; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center.
  • Koppikar P; Gerstner Sloan Kettering Graduate School of Biomedical Sciences.
  • Goel A; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center.
  • Wyder L; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center.
  • Tavares G; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Baffert F; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Pissot-Soldermann C; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Manley PW; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Gaul C; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Voshol H; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Levine RL; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Sellers WR; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center.
  • Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Radimerski T; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Cancer Discov ; 2(6): 512-523, 2012 Jun.
Article en En | MEDLINE | ID: mdl-22684457
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Quinasas Janus Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2012 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Quinasas Janus Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2012 Tipo del documento: Article País de afiliación: Suiza